Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Blockade and Radiotherapy in Advanced Solid Tumors
NCT05097781Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in solid tumor, sponsored by Ruijin Hospital. Primary endpoints: Objective response rate at 4 weeks and non-irradiated lesion control rate at 6 months. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05097781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097781.